Trans-acting aptazyme for conditional gene knockdown in eukaryotic cells.

Area of Science:

• Molecular Biology
• RNA Therapeutics
• Gene Regulation

Background:

• Hammerhead ribozymes are small, protein-independent RNA enzymes capable of cleaving specific RNA sequences.
• Precise control over hammerhead ribozyme activity is crucial for safe and accurate gene expression regulation.
• Existing methods lack sufficient control for targeted gene knockdown applications.

Purpose of the Study:

• To develop a controllable hammerhead ribozyme system for gene knockdown in eukaryotic cells.
• To engineer a hammerhead aptazyme responsive to theophylline for precise gene regulation.
• To investigate the efficacy of theophylline-inducible ribozymes for targeted gene silencing.

Main Methods:

• Intracellular selection of hammerhead aptazymes incorporating a theophylline aptamer.
• Development of novel cis-acting hammerhead aptazymes based on toxin protein IbsC.
• Testing theophylline-induced gene knockdown of targeted genes in eukaryotic cells.

Main Results:

• Three novel cis-acting hammerhead aptazymes were successfully generated.
• Theophylline efficiently induced trans-acting aptazymes to knock down target genes in eukaryotic cells.
• The T195 aptazyme demonstrated ligand-dependent and dose-dependent theophylline response with enhanced cleavage efficiency via multiplexing.

Conclusions:

• The developed hammerhead aptazymes offer precise, theophylline-inducible control over gene expression.
• These aptazymes represent a promising tool for targeted gene knockdown and therapeutic applications.
• Multiplex aptazyme incorporation can further enhance ribozyme cleavage efficiency for gene silencing.